TERN
Terns Pharmaceuticals, Inc. NASDAQ Listed Feb 5, 2021$52.95
Mkt Cap $4.8B
52w Low $2.65
99.5% of range
52w High $53.19
50d MA $49.45
200d MA $27.99
P/E (TTM)
-51.4x
EV/EBITDA
-29.4x
P/B
4.9x
Debt/Equity
0.0x
ROE
-9.6%
P/FCF
-45.8x
RSI (14)
—
ATR (14)
—
Beta
-0.38
50d MA
$49.45
200d MA
$27.99
Avg Volume
5.8M
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
1065 EAST HILLSDALE BLVD., SUITE 100 · FOSTER CITY, CA 94404 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.29 | -0.25 | +13.8% | 52.88 | -0.1% | -0.3% | -0.2% | -0.3% | -0.2% | -0.5% | — |
| Nov 10, 2025 | AMC | -0.30 | -0.27 | +10.0% | 19.12 | -1.7% | +7.6% | +6.2% | +8.4% | +18.0% | +33.7% | — |
| Aug 5, 2025 | AMC | -0.28 | -0.26 | +7.1% | 6.08 | -1.6% | -6.7% | -7.2% | +0.0% | +3.6% | +7.4% | — |
| May 8, 2025 | AMC | -0.29 | -0.26 | +10.3% | 3.00 | +1.3% | +1.3% | +0.7% | -3.3% | -7.3% | -7.0% | — |
| Mar 20, 2025 | AMC | -0.30 | -0.24 | +20.0% | 3.14 | +0.6% | +6.7% | +11.8% | +5.7% | -1.3% | -0.6% | — |
| Nov 12, 2024 | AMC | -0.33 | -0.28 | +15.2% | 7.17 | +2.2% | -5.4% | -8.6% | -13.9% | -20.5% | -17.6% | — |
| Aug 5, 2024 | AMC | -0.35 | -0.31 | +11.4% | 7.31 | +10.8% | -2.6% | -8.9% | -6.7% | -10.0% | -10.1% | — |
| May 13, 2024 | AMC | -0.36 | -0.30 | +16.7% | 5.89 | +1.9% | +1.7% | +1.7% | +4.2% | +0.2% | +6.1% | — |
| Mar 14, 2024 | AMC | -0.29 | -0.29 | +0.0% | 6.71 | +5.5% | +7.3% | -9.2% | -10.3% | -2.5% | -2.4% | — |
| Nov 14, 2023 | AMC | -0.31 | -0.42 | -35.5% | 3.55 | -1.1% | +8.5% | +2.8% | +4.5% | +5.6% | +6.2% | — |
| Aug 8, 2023 | AMC | -0.32 | -0.25 | +21.9% | 6.99 | +1.6% | -13.7% | -9.0% | -4.0% | -11.0% | -11.2% | — |
| May 15, 2023 | AMC | -0.28 | -0.31 | -10.7% | 11.87 | +3.1% | -9.5% | -13.0% | -15.4% | -15.0% | -5.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Oppenheimer | Downgrade | Outperform → Perform | — | $52.89 | $52.89 | +0.0% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% |
| Apr 14 | JP Morgan | Maintains | Overweight → Overweight | — | $52.61 | $52.67 | +0.1% | +0.1% | +0.2% | +0.2% | +0.1% | +0.2% |
| Mar 31 | Truist | Downgrade | Buy → Hold | — | $52.88 | $52.82 | -0.1% | -0.3% | -0.2% | -0.3% | -0.2% | -0.5% |
| Mar 30 | Barclays | Downgrade | Overweight → Equal Weight | — | $52.92 | $52.93 | +0.0% | -0.1% | -0.4% | -0.2% | -0.4% | -0.3% |
| Mar 26 | Citizens | Downgrade | Market Outperform → Market Perform | — | $52.86 | $52.84 | -0.0% | +0.6% | +0.1% | +0.0% | -0.3% | -0.1% |
| Mar 26 | TD Cowen | Downgrade | Buy → Hold | — | $52.86 | $52.84 | -0.0% | +0.6% | +0.1% | +0.0% | -0.3% | -0.1% |
| Mar 25 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $50.00 | $52.63 | +5.3% | +5.7% | +6.3% | +5.8% | +5.8% | +5.4% |
| Dec 11 | Citizens | Maintains | Market Outperform → Market Outperform | — | $44.61 | $45.15 | +1.2% | +5.6% | +0.9% | -1.3% | -3.8% | -5.9% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.23 | $40.00 | -0.6% | +5.8% | +10.9% | +17.1% | +11.9% | +9.4% |
| Dec 9 | Mizuho | Maintains | Outperform → Outperform | — | $40.23 | $40.00 | -0.6% | +5.8% | +10.9% | +17.1% | +11.9% | +9.4% |
| Dec 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $40.23 | $40.00 | -0.6% | +5.8% | +10.9% | +17.1% | +11.9% | +9.4% |
| Dec 9 | BMO Capital | Maintains | Outperform → Outperform | — | $40.23 | $40.00 | -0.6% | +5.8% | +10.9% | +17.1% | +11.9% | +9.4% |
| Dec 9 | Truist | Maintains | Buy → Buy | — | $40.23 | $40.00 | -0.6% | +5.8% | +10.9% | +17.1% | +11.9% | +9.4% |
| Dec 9 | Barclays | Maintains | Overweight → Overweight | — | $40.23 | $40.00 | -0.6% | +5.8% | +10.9% | +17.1% | +11.9% | +9.4% |
| Nov 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $29.35 | $29.51 | +0.5% | -2.0% | -4.2% | -6.2% | -12.1% | -6.3% |
| Nov 25 | Barclays | Maintains | Overweight → Overweight | — | $28.04 | $28.80 | +2.7% | +4.7% | +2.5% | +0.2% | -1.8% | -8.0% |
| Nov 19 | Truist | Maintains | Buy → Buy | — | $27.56 | $27.48 | -0.3% | -1.6% | -5.3% | -4.5% | +1.7% | +6.5% |
| Nov 18 | BMO Capital | Maintains | Outperform → Outperform | — | $25.56 | $25.27 | -1.1% | +7.8% | +6.1% | +2.2% | +3.0% | +9.7% |
| Nov 13 | Mizuho | Maintains | Outperform → Outperform | — | $20.30 | $20.48 | +0.9% | +2.1% | +11.1% | +25.9% | +35.8% | +33.6% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $19.12 | $18.80 | -1.7% | +7.6% | +6.2% | +8.4% | +18.0% | +33.7% |
| Nov 4 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $14.03 | $15.50 | +10.5% | +24.2% | +29.7% | +30.1% | +31.6% | +36.3% |
| Nov 4 | Mizuho | Maintains | Outperform → Outperform | — | $14.03 | $15.50 | +10.5% | +24.2% | +29.7% | +30.1% | +31.6% | +36.3% |
| Nov 4 | BMO Capital | Maintains | Outperform → Outperform | — | $14.03 | $15.50 | +10.5% | +24.2% | +29.7% | +30.1% | +31.6% | +36.3% |
| Nov 4 | Truist | Maintains | Buy → Buy | — | $14.03 | $15.50 | +10.5% | +24.2% | +29.7% | +30.1% | +31.6% | +36.3% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $14.03 | $15.50 | +10.5% | +24.2% | +29.7% | +30.1% | +31.6% | +36.3% |
| Nov 3 | Jefferies | Maintains | Buy → Buy | — | $8.26 | $14.05 | +70.1% | +69.9% | +111.0% | +120.2% | +120.9% | +123.6% |
| Nov 3 | William Blair | Upgrade | Market Perform → Outperform | — | $8.26 | $14.05 | +70.1% | +69.9% | +111.0% | +120.2% | +120.9% | +123.6% |
| Oct 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.14 | $7.72 | -5.2% | -7.9% | -4.5% | -1.0% | +5.5% | -1.5% |
| Oct 22 | Barclays | Maintains | Overweight → Overweight | — | $8.12 | $7.14 | -12.1% | +0.2% | -7.6% | -4.3% | -0.7% | +5.8% |
| Oct 22 | Mizuho | Maintains | Outperform → Outperform | — | $8.12 | $7.14 | -12.1% | +0.2% | -7.6% | -4.3% | -0.7% | +5.8% |
| Oct 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.12 | $7.14 | -12.1% | +0.2% | -7.6% | -4.3% | -0.7% | +5.8% |
| May 13 | BMO Capital | Maintains | Outperform → Outperform | — | $3.02 | $3.02 | +0.0% | -4.0% | -7.9% | -7.6% | -4.6% | +4.3% |
| Apr 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.40 | $2.37 | -1.2% | +12.9% | +16.7% | +20.0% | +27.1% | +21.7% |
| Dec 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.36 | $6.46 | +1.6% | +11.3% | +1.3% | +3.0% | +3.5% | +8.8% |
| Dec 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.36 | $6.46 | +1.6% | +11.3% | +1.3% | +3.0% | +3.5% | +8.8% |
| Dec 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.36 | $6.46 | +1.6% | +11.3% | +1.3% | +3.0% | +3.5% | +8.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.17 | $7.33 | +2.2% | -5.4% | -8.6% | -13.9% | -20.5% | -17.6% |
| Sep 16 | BMO Capital | Maintains | Outperform → Outperform | — | $8.96 | $9.26 | +3.3% | +5.0% | +7.5% | +14.0% | +12.1% | +11.8% |
| Sep 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.12 | $9.64 | +5.7% | +23.1% | +17.1% | +4.3% | -1.8% | +3.2% |
| Sep 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.62 | $7.58 | -0.5% | -5.1% | -3.8% | -2.1% | +2.5% | +19.7% |
| Aug 6 | BMO Capital | Maintains | Outperform → Outperform | — | $7.31 | $8.10 | +10.8% | -2.6% | -8.9% | -6.7% | -10.0% | -10.1% |
| May 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.89 | $6.00 | +1.9% | +1.7% | +1.7% | +4.2% | +0.2% | +6.1% |
| Apr 30 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.10 | $5.20 | +2.0% | -1.0% | -0.4% | +3.7% | +6.7% | +13.5% |
| Apr 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.10 | $5.20 | +2.0% | -1.0% | -0.4% | +3.7% | +6.7% | +13.5% |
| Mar 27 | UBS | Maintains | Buy → Buy | — | $6.16 | $6.25 | +1.5% | +0.0% | +6.5% | +15.3% | +7.8% | -2.6% |
| Mar 18 | JMP Securities | Maintains | Outperform → Outperform | — | $7.20 | $7.10 | -1.4% | -15.4% | -16.4% | -9.2% | -9.0% | -8.3% |
| Mar 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.71 | $7.08 | +5.5% | +7.3% | -9.2% | -10.3% | -2.5% | -2.4% |
| Mar 15 | BMO Capital | Maintains | Outperform → Outperform | — | $6.71 | $7.08 | +5.5% | +7.3% | -9.2% | -10.3% | -2.5% | -2.4% |
| Jan 10 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.75 | $6.65 | -1.5% | -9.2% | -13.2% | -13.2% | -14.5% | -17.2% |
| Dec 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.07 | $6.06 | -0.2% | +7.1% | +11.4% | +12.2% | +9.7% | +6.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Terns Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Terns Pharmaceuticals experienced executive leadership changes with departures and new officer appointments, though the filing summary lacks specific details about compensation arrangements or director election outcomes.
May 5
SC TO-T/A
! Medium
Terns Pharmaceuticals, Inc. -- Tender Offer Amendment
Merck's tender offer to acquire Terns Pharmaceuticals at $53 per share represents a significant deal combining Merck's scale with Terns' drug development capabilities.
May 5
8-K · 7.01
! Medium
Terns Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Terns Pharmaceuticals received FDA Breakthrough Therapy Designation for TERN-701, an oral BCR-ABL1 inhibitor for Ph+CML patients, potentially accelerating development and regulatory approval timelines.
Apr 27
SC TO-T
!!! Very High
Terns Pharmaceuticals, Inc. -- Tender Offer
Merck is acquiring Terns Pharmaceuticals for $53 per share in a tender offer, gaining access to Terns' pipeline of metabolic disease treatments and expanding its pharmaceutical portfolio.
Apr 24
SC TO-T
!!! Very High
Unknown — Tender Offer
Merck's tender offer for Tern Pharmaceuticals signals acquisition intent, potentially indicating confidence in Tern's pipeline value and providing Tern shareholders with liquidity while offering Merck near-term asset diversification.
Apr 7
8-K
Unknown — 8-K Filing
Tern Pharmaceuticals agreed to a merger transaction that will proceed through a tender offer followed by a statutory merger, creating potential near-term shareholder liquidity and eliminating uncertainty about the company's independent future.
Mar 25
Data updated apr 27, 2026 4:29am
· Source: massive.com